BCR-ABL1 Kinase Domain Mutation Analysis

Testing Information

Testing Specialties

Specimen Handling

Client Services

Lab Expertise

Suite of Services

Research & Development

Education

ARUP's Laboratory Test Directory

BCR-ABL1 Kinase Domain Mutation Analysis : 0040138

Time Sensitive

Additional Technical Information

Mnemonic: BCRABL MUT

Methodology:	Polymerase Chain Reaction/Sequencing
Performed:	Varies
Reported:	10-12 days
Specimen Required:	Collect: Lavender (EDTA) or bone marrow (EDTA). Specimen Preparation: Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL whole blood or 1 mL bone marrow) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens. Stability (collection to initiation of testing): Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable

Reference Interval: By report
Interpretive Data:	Refer to report See Compliance Statement B: www.aruplab.com/CS
Note:	Assay detects more than 90 percent of the mutations that may lead to imatinib resistance.
CPT Code(s):	81403, G0452
Cross References:	ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis) , ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis) , BCR-ABL1 Mutation (BCR-ABL1 Kinase Domain Mutation Analysis) , Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis) , Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis) , Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)